Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 2/20 | 0.67 |
| ▸ | NT5E | P21589 | 8/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | ALB | P02768 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GLI1 | P08151 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | RORC | P51449 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.64 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.64 |
| ▸ | CETP | P11597 | 1/20 | 0.62 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914992 | 0.93 | PRKCG (0.69) | PRKCGNT5EPRKCDPTPN1ALB | |
| SCHEMBL12330536 | 0.92 | PRKCG (0.68) | PRKCGNT5EPRKCDPTPN1ALB | |
| SCHEMBL12279137 | 0.92 | PRKCG (0.79) | PRKCGNT5EPRKCDPTPN1ALB | |
| SCHEMBL13890818 | 0.91 | NT5E (0.69) | PRKCGNT5EPRKCDPTPN1CETP | |
| SCHEMBL9130088 | 0.91 | NT5E (0.69) | PRKCGNT5EPRKCDPTPN1CETP | |
| SCHEMBL14124010 | 0.91 | NT5E (0.69) | PRKCGNT5EPRKCDPTPN1CETP | |
| SCHEMBL10214444 | 0.91 | NT5E (0.69) | PRKCGNT5EPRKCDPTPN1CETP | |
| SCHEMBL14156586 | 0.91 | NT5E (0.69) | PRKCGNT5EPRKCDPTPN1CETP | |
| SCHEMBL12557822 | 0.91 | NT5E (0.69) | PRKCGNT5EPRKCDPTPN1CETP | |
| SCHEMBL9129432 | 0.91 | NT5E (0.69) | PRKCGNT5EPRKCDPTPN1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| US-8802727-B2 | Pharmaceutically acceptable salts of betulinic acid derivatives | HETERO RESEARCH FOUNDATION, HETERO DRUGS LIMITED (IN) | 2014-08-12 | — | — | US | disclosed |
| US-8802727-B2 | Pharmaceutically acceptable salts of betulinic acid derivatives | HETERO RESEARCH FOUNDATION, HETERO DRUGS LIMITED (IN) | 2014-08-12 | — | — | US | disclosed |
| US-20140221328-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF NOVEL BETULINIC ACID DERIVATIVES | HETERO LABS LIMITED (IN) | 2014-08-07 | — | — | US | disclosed |
| US-20140221328-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF NOVEL BETULINIC ACID DERIVATIVES | HETERO LABS LIMITED (IN) | 2014-08-07 | — | — | US | disclosed |
| WO-2012095705-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF NOVEL BETULINIC ACID DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2012-07-19 | — | — | WO | disclosed |
| US-20110218204-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF NOVEL BETULINIC ACID DERIVATIVES | HETERO RESEARCH FOUNDATION, HETERO DRUGS LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218204-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF NOVEL BETULINIC ACID DERIVATIVES | HETERO RESEARCH FOUNDATION, HETERO DRUGS LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| WO-2011007230-A2 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | PRKCG 2513/4885NT5E 1020/4885PRKCD 1630/4885 |
| US-20110218204-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF NOVEL BETULINIC ACID DERIVATIVES | BET1, NFATC1, PGGT1B | PRKCG 1058/4885NT5E 1694/4885PRKCD 1416/4885 |
| US-20140221328-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF NOVEL BETULINIC ACID DERIVATIVES | BET1, NFATC1, PGGT1B | PRKCG 1058/4885NT5E 1694/4885PRKCD 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.